Immunotherapy represents a transformative approach to cancer treatment, leveraging the body’s immune system to combat the disease. As a medical oncologist specializing in this field, I have witnessed firsthand the remarkable advancements in immunotherapythat have significantly extended patient survival and improved quality of life.
Oncocit’s Innovative Therapies
At Oncocit, we are at the forefront of developing cutting-edge immunotherapeutic treatments. Our commitment to research and collaboration with global institutions enables us to lead in designing therapies that specifically target cancer cells while preserving healthy tissue. This precision not only enhances treatment efficacy but also reduces the side effects commonly associated with conventional cancer treatments.
Oncocit’s Scientific Foundations: Personalization and Optimization of Therapies
As part of our advanced research efforts, Oncocit has developed innovative methods based on a comparative evaluation of tumor proteins extracted from both biopsies and cell lines. This approach ensures unprecedented personalization in immunotherapy and targeted therapy by providing high-quality tumor proteins through an efficient biotechnological process.
- High-Quality Tumor Protein Production: Advanced protocols for antigen recovery were implemented, emphasizing the extraction of key epitopes such as neoantigens linked to specific mutations. Proteins derived from cell lines like SaOS-2 (osteosarcoma), HT-29 and HCT116 (colon cancer), and MCF-7 (breast cancer) exhibited a significantly lower degradation index (<10%) compared to those obtained from biopsies (>30%).
- Efficient Induction of Immune Responses: Tumor proteins were used in co-cultures with dendritic cells (DCs), achieving outstanding activation of maturation markers such as CD80/CD86 (exceeding 85%) and high secretion levels of immunomodulatory cytokines (IL-12 and TNF-α >50 pg/mL). This breakthrough ensures reproducible and effective immune stimulation.
- Focus on Key Mutated Proteins: The production of proteins like BAX, BCL-2, P53, and mutated KRAS demonstrated superior functionality in eliciting targeted immune responses, presenting a more accessible and effective alternative compared to traditional recombinant proteins.
The Impact on Patient Outcomes
The impact of these therapies on patient outcomes cannot be overstated. We have witnessed remarkable success stories where patients, previously deemed untreatable, have achieved significant remission and, in some cases, complete recovery.
Real-World Success Stories
I have had the privilege of treating numerous patients who have benefited from these innovative therapies. Their stories are a testament to the potential of immunotherapy not only to extend life but also to improve its quality.
Conclusion: The Future of Cancer Treatment
As we continue to advance in this exciting field, our goal at Oncocit is not only to treat cancer more effectively but to reach a future where cancer can be managed as a chronic condition or even cured. Combining advanced research, biotechnological personalization, and a commitment to quality positions us as leaders in this immunotherapy revolution.